Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

QNCX

Quince Therapeutics Inc

May 07 • 12:02PM ET

1.27

+0.05 4.10 %

Healthcare • Biotechnology • USA • Nano • NASD

Peers: LRMR BIVI IMUX ALZN SNGX

| Held by: VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-16.43	Insider Own	13.20%	Shs Outstand	16.30M	Perf Week	-3.05%
Market Cap	20.71M	Forward P/E	-	EPS next Y	-0.54	Insider Trans	-2.27%	Shs Float	14.15M	Perf Month	-30.64%
Enterprise Value	21.43M	PEG	-	EPS next Q	-1.41	Inst Own	15.74%	Short Float	13.79%	Perf Quarter	-13.07%
Income	-83.98M	P/S	-	EPS this Y	39.41%	Inst Trans	-	Short Ratio	0.18	Perf Half Y	-92.06%
Sales	0.00M	P/B	-	EPS next Y	91.73%	ROA	-76.42%	Short Interest	1.95M	Perf YTD	-96.21%
Book/sh	-6.41	P/C	1.17	EPS next 5Y	-	ROE	-247.78%	52W High	45.50 -97.21%	Perf Year	-87.79%
Cash/sh	1.09	P/FCF	-	EPS past 3/5Y	-2.82% 8.64%	ROIC	-	52W Low	0.80 58.75%	Perf 3Y	-91.91%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.09% 18.84%	Perf 5Y	-99.66%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-25.06%	Oper. Margin	-	ATR (14)	0.23	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.53	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	43.53	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.53	EPS Q/Q	-149.43%	SMA20	-2.28%	Beta	1.45	Target Price	70.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	9.24%	Rel Volume	0.09	Prev Close	1.22
Employees	38	LT Debt/Eq	-	Earnings	Mar 03	SMA200	-91.71%	Avg Volume	10.64M	Price	1.27
IPO	May 09, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	16.81% -	Trades		Volume	384,855	Change	4.10%

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)